Trikafta (elexacaftor/tezacaftor/ivacaftor) was associated with improved lung function and fewer pulmonary exacerbations, or sudden worsening of lung symptoms, in children ages 6 to 11 with cystic fibrosis (CF), a real-world study found. The treatment was also associated with improved nutritional status, fewer hospitalizations and antibiotic treatments, and reduced…

My late daughter, Jasmine, was 16 when she attended her first school dance. For most teenagers, this would have been just another Friday night, involving some awkward slow songs and maybe a few embarrassing photos. But for Jasmine, it was something she had been dreaming about for years that I…

A Phase 2a clinical trial testing RCT2100, Recode Therapeutics’ investigational inhaled mRNA therapy for cystic fibrosis (CF), is fully enrolled, with results expected by the end of the year, the company announced. The clinical updates were part of a broader company announcement focused on Recode’s CF programs, which also…

For children with cystic fibrosis (CF) who are taking Trikafta (elexacaftor/tezacaftor/ivacaftor), weight gain was associated with decreasing levels of inflammation in the body, a Swiss study reports. The association was seen in both short- and long-term analyses after treatment began. Changes in inflammation and body mass index (BMI),…

Living with cystic fibrosis (CF) made me very aware of breathing. Before my double-lung transplant eight years ago, I’d check the weather before committing to any plans, because protecting my lung health from allergens, weather triggers, and anything that could cause inflammation was essential to my well-being. Since…

Cutting-edge DNA sequencing technologies for microbial surveillance have the potential to revolutionize how lung infections in people with cystic fibrosis (CF) are diagnosed and managed, according to a new review study. However, researchers noted that there are still challenges that need to be overcome before these technologies can be…